Envestnet Asset Management
KRYS icon

Envestnet Asset Management’s Krystal Biotech KRYS Stock Holding History

Envestnet Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.91M Buy
13,212
+1,229
+10% +$367K ﹤0.01% 2478
2026
Q1 		$3.1M Buy
11,983
+1,406
+13% +$374K ﹤0.01% 2679
2025
Q4 		$2.61M Sell
10,577
-2,531
-19% -$533K ﹤0.01% 2632
2025
Q3 		$2.31M Sell
13,108
-2,008
-13% -$301K ﹤0.01% 2788
2025
Q2 		$2.08M Buy
15,116
+2,717
+22% +$399K ﹤0.01% 2802
2025
Q1 		$2.24M Buy
12,399
+769
+7% +$129K ﹤0.01% 2660
2024
Q4 		$1.82M Buy
11,630
+121
+1% +$21.5K ﹤0.01% 2754
2024
Q3 		$2.09M Buy
11,509
+4,501
+64% +$868K ﹤0.01% 2623
2024
Q2 		$1.29M Buy
7,008
+2,535
+57% +$426K ﹤0.01% 2868
2024
Q1 		$796K Buy
4,473
+1,841
+70% +$256K ﹤0.01% 3173
2023
Q4 		$327K Sell
2,632
-1,006
-28% -$112K ﹤0.01% 3564
2023
Q3 		$422K Buy
+3,638
New +$444K ﹤0.01% 3337

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Envestnet Asset Management's KRYS Position: Q2 2026 in Review

Envestnet Asset Management increased its Krystal Biotech (KRYS) stake by 10% in Q2 2026, buying an estimated $367K and bringing the position to 13,212 shares worth $4.91M. The position accounts for ﹤0.01% of the portfolio, ranked #2478.

Envestnet Asset Management first reported a position in KRYS in Q3 2023 and has held it in 12 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Envestnet Asset Management held 13,212 shares of Krystal Biotech worth $4.91M as of Q2 2026.
  • Envestnet Asset Management bought 1,229 Krystal Biotech shares in Q2 2026, an estimated $367K.
  • Krystal Biotech made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #2478 holding.
  • Envestnet Asset Management first reported a position in Krystal Biotech in Q3 2023 and has held it in 12 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.